[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100461469":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":40,"centralContacts":44,"locations":49,"responsibleParty":67,"collaborators":70,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":33,"eligibilityCriteria":79,"healthyVolunteers":76,"sex":80,"minAge":81,"maxAge":33,"enrollmentInfo":82,"targetDuration":33,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":52,"whyStopped":33,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Columbia University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","ACTIVE_COMPARATOR","OSA patients who adhered or did not adhere with CPAP who are randomized to receive atorvastatin 10 mg daily.",[13,14],"Drug: Atorvastatin 10mg","Other: Continuous Positive Airway Pressure Therapy",{"label":16,"type":17,"description":18,"interventionNames":19},"Control","PLACEBO_COMPARATOR","OSA patients who adhered or did not adhere with CPAP who are randomized to receive placebo daily.",[20,14],"Drug: Placebo",[22,29,34],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Atorvastatin 10mg","Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.",[9],[28],"statin",{"type":23,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Placebo","Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.",[16],null,{"type":6,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Continuous Positive Airway Pressure Therapy","CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP.",[16,9],[39],"CPAP",[41],{"name":42,"affiliation":5,"role":43},"Sanja Jelic, MD","PRINCIPAL_INVESTIGATOR",[45],{"name":42,"role":46,"phone":47,"phoneExt":33,"email":48},"CONTACT","2125438875","sj366@cumc.columbia.edu",[50],{"facility":51,"status":52,"city":53,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Columbia University Irving Medical Center","RECRUITING","New York","10032","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-74.00597,40.71427,{"lat":61,"lon":60},[64,66],{"name":42,"role":46,"phone":65,"phoneExt":33,"email":48},"212-543-8875",{"name":42,"role":43,"phone":33,"phoneExt":33,"email":33},{"type":43,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"Sanja Jelic","Associate Professor of Medicine",[71],{"name":72,"class":73},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100461469","phase-1-vascular-endothelial-dysfunction-in-sleep-apnea-100461469",false,"NCT05289063","Vascular Endothelial Dysfunction in Sleep Apnea","Inclusion Criteria:\n\n* Aged ≥18 years\n* Newly diagnosed with obstructive sleep apnea (OSA) who were never treated with CPAP. OSA is defined as apnea-hypopnea index (AHI) ≥5 events\u002Fhour of sleep.\n\nExclusion Criteria:\n\n* A history of coronary artery disease, heart failure, stroke, diabetes, malignancy, chronic pulmonary, kidney or rheumatologic disease, muscle pain\u002Ffatigue, smoking within the past 5 years\n* Regular use of any medications","ALL","18 Years",{"count":83,"type":84},110,"ESTIMATED","INTERVENTIONAL",[87],"PHASE1","This double-blind placebo-controlled parallel group randomized study design will be used to test whether 4 weeks of atorvastatin 10 mg daily reduces levels of inflammatory markers in OSA patients treated with CPAP (standard of care). The purpose of this study is to investigate: 1) whether statins reduce endothelial inflammation and pro-thrombotic conditions in OSA, including in patients adherent to CPAP (Aim 1); and 2) whether statins reduce endothelial inflammation and pro-thrombotic conditions by improving endothelial cholesterol metabolism and trafficking in OSA (Aim 2).",[90],"Obstructive Sleep Apnea of Adult",[39,92],"Atorvastatin","2026-02-11",{"date":95,"type":96},"2026-02-13","ACTUAL",{"date":98,"type":96},"2022-10-03",{"date":100,"type":84},"2027-02-28",{"name":5,"class":6},1]